Inflammatory Markers Significantly Increased in Patients Treated with Obinotuzumab for Lymphoproliferative Diseases
Krzysztof Gawronski, Nadia Hussein, Piotr Rzepecki, Masaaki Noguchi · 2024
Read Inflammatory Markers Significantly Increased in Patients Treated with Obinotuzumab for Lymphoproliferative Diseases by Krzysztof Gawronski, Nadia Hussein, Piotr Rzepecki, Masaaki Noguchi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641938.txt.
Description
Krzysztof Gawronski, Nadia Hussein, and Piotr Rzepecki warn that a modern antibody drug for blood cancers sends infection markers soaring even when no infection is present. The drug targets a protein on B cells and is used in chronic lymphocytic leukemia and follicular lymphoma. The team followed twenty-two patients, drawing blood daily for a week after infusion and culturing for bacteria.
Every patient showed sharp rises in C-reactive protein and procalcitonin in the first days after treatment. The procalcitonin change was highly significant statistically. Yet these spikes usually signaled no infection and caused no harm. The authors urge clinicians not to mistake this drug reaction for sepsis when judging early blood tests.
Catalog record
| CREATOR | Krzysztof Gawronski, Nadia Hussein, Piotr Rzepecki, Masaaki Noguchi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |